PE20070405A1 - Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a - Google Patents

Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a

Info

Publication number
PE20070405A1
PE20070405A1 PE2006000963A PE2006000963A PE20070405A1 PE 20070405 A1 PE20070405 A1 PE 20070405A1 PE 2006000963 A PE2006000963 A PE 2006000963A PE 2006000963 A PE2006000963 A PE 2006000963A PE 20070405 A1 PE20070405 A1 PE 20070405A1
Authority
PE
Peru
Prior art keywords
chloro
xanthine
agonists
nicotinic acid
pentil
Prior art date
Application number
PE2006000963A
Other languages
English (en)
Inventor
Richard Jonathan Daniel Hatley
Andrew Mcmurtrie Mason
Ivan Leo Pinto
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20070405A1 publication Critical patent/PE20070405A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE XANTINA DE FORMULA (I) DONDE R1 ES -(ALQUILEN)m-X-(ALQUILENO)n-Y, DONDE m ES 3 O 4; n ES 0 O 1; X ES HETEROARILO DE 5 A 10 MIEMBROS O HETEROCICLILO DE 4 A 12 MIEMBROS; Y ES ARILO(C6-C12), HETEROARILO DE 5 A 10 MIEMBROS U O-ARILO(C6-C12); R2 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON CICLOALQUILO(C3-C8), HALOALQUILO(C1-C6), HALOGENO, ENTRE OTROS; R3 ES HALOGENO. SON COMPUESTOS PREFERIDOS: 8-CLORO-3-PENTIL-1-(3-{1-[(2,4,6-TRIFLUOROFENIL)METIL]-1H-PIRAZOL-4-IL}PROPIL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA, 8-CLORO-1-(3-{1-[(2-CLORO-4-FLUOROFENIL)METIL]-1H-PIRAZOL-4-IL}PROPIL)-3-PENTIL-3,7-DIHIDRO-1H-PURINA-2,6-DIONA, 8-CLORO-1-(3-{1-[(2,6-DIFLUOROFENIL)METIL]-1H-PIRAZOL-4-IL}PROPIL)-3-PENTIL-3,7-DIHIDRO-1H-PURINA-2,6-DIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE ACIDO NICOTINICO HM74A SIENDO UTILES EN EL TRATAMIENTO DE DISLIPIDEMIA, HIPERCOLESTEROLEMIA, DIABETES MELLITUS TIPO 2, OBESIDAD
PE2006000963A 2005-08-10 2006-08-08 Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a PE20070405A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds

Publications (1)

Publication Number Publication Date
PE20070405A1 true PE20070405A1 (es) 2007-05-06

Family

ID=37189397

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000963A PE20070405A1 (es) 2005-08-10 2006-08-08 Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a

Country Status (29)

Country Link
US (3) US8143264B2 (es)
EP (3) EP2272848B1 (es)
JP (2) JP5112316B2 (es)
KR (2) KR20080034993A (es)
AR (1) AR055369A1 (es)
AT (1) ATE487719T1 (es)
AU (2) AU2006278216A1 (es)
BR (2) BRPI0615145A2 (es)
CA (2) CA2626723A1 (es)
CR (2) CR9748A (es)
CY (1) CY1111757T1 (es)
DE (1) DE602006018151D1 (es)
DK (1) DK1912991T3 (es)
EA (2) EA200800564A1 (es)
ES (1) ES2401128T3 (es)
HK (1) HK1116779A1 (es)
HR (1) HRP20100725T1 (es)
IL (2) IL189081A0 (es)
MA (2) MA29693B1 (es)
MX (2) MX2008001931A (es)
MY (1) MY142067A (es)
NO (2) NO20081212L (es)
NZ (1) NZ565494A (es)
PE (1) PE20070405A1 (es)
PL (1) PL1912991T3 (es)
PT (1) PT1912991E (es)
SI (1) SI1912991T1 (es)
TW (1) TW200800217A (es)
WO (2) WO2007017262A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
AU2005212816C1 (en) * 2004-02-14 2010-03-04 Glaxosmithkline Llc Novel compounds
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
PT1912991E (pt) * 2005-08-10 2011-01-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de hm74a
TWI423978B (zh) 2006-06-23 2014-01-21 Incyte Corp 作為hm74a同效劑之嘌呤酮衍生物(二)
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
KR101743783B1 (ko) 2008-12-08 2017-06-05 글락소스미스클라인 엘엘씨 신규 화합물
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PE20130751A1 (es) * 2010-08-16 2013-06-21 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrieno
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013269800A1 (en) * 2012-05-30 2014-10-09 F. Hoffmann-La Roche Ag Triazolo compounds as PDE10 inhibitors
MY189912A (en) * 2013-03-15 2022-03-21 Hydra Biosciences Llc Substituted xanthines and methods of use thereof
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994141A4 (en) 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
JP6417401B2 (ja) * 2013-05-10 2018-11-07 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
CN104211702B (zh) * 2013-05-29 2018-08-31 中国医学科学院药物研究所 取代黄嘌呤类化合物及其制备方法和用途
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
CN110461838B (zh) * 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
AR128431A1 (es) * 2022-02-03 2024-05-08 De Shaw Res Llc Compuestos de uracilo n3-sustituidos como inhibidores de trpa1

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
AU3725893A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
CA2112239C (en) 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
MXPA01010143A (es) 1999-04-09 2003-07-14 Cell Therapeutics Inc Derivados de xantina y analogos como inhibidores de transmision de senales celulares.
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
EP1953162B9 (de) 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
ATE388951T1 (de) * 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
EP1338595B1 (en) * 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
AU2005212816C1 (en) * 2004-02-14 2010-03-04 Glaxosmithkline Llc Novel compounds
WO2006045564A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
JP2008517029A (ja) * 2004-10-22 2008-05-22 スミスクライン・ビーチャム・コーポレイション Hm74a受容体活性を有するキサンチン誘導体
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
EP1848699A1 (en) 2005-02-14 2007-10-31 Smithkline Beecham Corporation Anthranilic acid derivatives as hm74a receptor agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
PT1912991E (pt) * 2005-08-10 2011-01-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de hm74a
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
KR101743783B1 (ko) 2008-12-08 2017-06-05 글락소스미스클라인 엘엘씨 신규 화합물

Also Published As

Publication number Publication date
ES2401128T3 (es) 2013-04-17
EA014556B1 (ru) 2010-12-30
CA2626723A1 (en) 2007-02-15
NZ565494A (en) 2011-06-30
EP1912991B1 (en) 2010-11-10
EP1912992A1 (en) 2008-04-23
AR055369A1 (es) 2007-08-22
TW200800217A (en) 2008-01-01
JP5112316B2 (ja) 2013-01-09
EA200800564A1 (ru) 2008-08-29
PL1912991T3 (pl) 2011-04-29
WO2007017261A1 (en) 2007-02-15
KR20080038396A (ko) 2008-05-06
ATE487719T1 (de) 2010-11-15
MX2008001931A (es) 2008-03-24
IL189083A0 (en) 2008-08-07
SI1912991T1 (sl) 2011-03-31
MA29692B1 (fr) 2008-08-01
KR20080034993A (ko) 2008-04-22
IL189081A0 (en) 2008-08-07
MA29693B1 (fr) 2008-08-01
AU2006278215A1 (en) 2007-02-15
US20100168122A1 (en) 2010-07-01
NO20081212L (no) 2008-05-06
EP2272848B1 (en) 2012-12-26
CR9749A (es) 2008-05-22
CA2618963A1 (en) 2007-02-15
PT1912991E (pt) 2011-01-17
CY1111757T1 (el) 2015-10-07
HK1116779A1 (en) 2009-01-02
EP2272848A1 (en) 2011-01-12
US20100179128A1 (en) 2010-07-15
AU2006278216A1 (en) 2007-02-15
EP1912991A1 (en) 2008-04-23
US8143264B2 (en) 2012-03-27
EA200800555A1 (ru) 2008-08-29
JP2009504591A (ja) 2009-02-05
JP2009504592A (ja) 2009-02-05
NO20081211L (no) 2008-05-08
HRP20100725T1 (hr) 2011-01-31
BRPI0614270A2 (pt) 2011-03-22
WO2007017262A1 (en) 2007-02-15
BRPI0615145A2 (pt) 2009-11-03
DK1912991T3 (da) 2011-02-21
DE602006018151D1 (de) 2010-12-23
CR9748A (es) 2008-05-05
MY142067A (en) 2010-08-30
US20110257205A1 (en) 2011-10-20
MX2008001929A (es) 2008-03-24

Similar Documents

Publication Publication Date Title
PE20070405A1 (es) Compuestos derivados de xantina como agonistas del receptor de acido nicotinico hm74a
AU2010338011B2 (en) Novel pyrimidine compounds as mTOR and P13K inhibitors
ES2434337T3 (es) Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
JP2006522812A5 (es)
RU2007116038A (ru) Циклические диарилмочевины, используемые в качестве ингибиторов тирозинкиназы
PE20061067A1 (es) Derivados de pirimidina
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20051159A1 (es) Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina
WO2011152485A1 (ja) 新規4,5-縮環ピリミジン誘導体
JP6403751B2 (ja) 5−チアゾールカルボキサミン誘導体及びbtk阻害剤としてのその使用
PE20061351A1 (es) COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)
PE20071168A1 (es) Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip
DE60027700D1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
US20210269427A1 (en) Process For Preparing Aminopyrimidine Derivatives
RU2717830C2 (ru) Способ получения азотсодержащего гетероциклического соединения и его промежуточного соединения
RU2010147416A (ru) Соединения, обладающие антагонистической активностью относительно рецепторов npy y5
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
PE20090629A1 (es) Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7
EP2501233B1 (en) Quinazoline compounds
ES2685070T3 (es) Compuesto bicíclico que contiene azufre

Legal Events

Date Code Title Description
FC Refusal